{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:08:35Z","timestamp":1777590515405,"version":"3.51.4"},"reference-count":121,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.11.003","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:52:52Z","timestamp":1490287972000},"page":"335-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T\/NK-cell Lymphomas"],"prefix":"10.1016","volume":"31","author":[{"given":"Tejaswini M.","family":"Dhawale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.11.003_bib1","series-title":"World Health Organization classification of tumours","author":"Swerdlow","year":"2008"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.beha.2013.04.008","article-title":"Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T\/NK-cell lymphomas","volume":"26","author":"Shustov","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.003_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","article-title":"Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis?","volume":"30","author":"Iqbal","year":"2016","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.003_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.critrevonc.2010.07.007","article-title":"Peripheral T-cell lymphoma\u2013not otherwise specified","volume":"79","author":"Savage","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.003_bib6","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1016\/j.hoc.2016.11.003_bib7","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.003_bib8","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2016.11.003_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-\u03b4,\u03b3 Inhibitor, Shows Activity in Patients with Relapsed\/Refractory T-Cell Lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.003_bib10","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed September 6, 2015."},{"issue":"12","key":"10.1016\/j.hoc.2016.11.003_bib11","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.003_bib12","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"Yang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.003_bib15","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","article-title":"Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center","volume":"26","author":"Loirat","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOH.0000000000000261","article-title":"The curious origins of angioimmunoblastic T-cell lymphoma","volume":"23","author":"Cort\u00e9s","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.003_bib20","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.003_bib21","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminhematol.2013.11.003","article-title":"Pathology of peripheral T-cell lymphomas: where do we stand?","volume":"51","author":"Gaulard","year":"2014","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-Cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2016.11.003_bib24","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2016.11.003_bib25","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2016.11.003_bib26","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2016.11.003_bib27","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell\u00a0lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11864-013-0232-x","article-title":"Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?","volume":"14","author":"Lunning","year":"2013","journal-title":"Curr Treat Options Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2016.11.003_bib29","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib30","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.003_bib31","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience","volume":"78","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"issue":"14","key":"10.1016\/j.hoc.2016.11.003_bib33","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2016.11.003_bib34","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.003_bib35","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin\u2019s Lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"Project","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.003_bib36","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib38","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/asheducation-2015.1.550","article-title":"Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma","volume":"2015","author":"Beaven","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","article-title":"Anaplastic large cell lymphoma, ALK-positive","volume":"83","author":"Ferreri","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"32","key":"10.1016\/j.hoc.2016.11.003_bib40","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.003_bib41","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.003_bib42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12060","article-title":"Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma","volume":"90","author":"Zhang","year":"2013","journal-title":"Eur J Haematol"},{"issue":"14","key":"10.1016\/j.hoc.2016.11.003_bib43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.003_bib44","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.003_bib45","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.003_bib46","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib47","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.3324\/haematol.2015.131151","article-title":"Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma","volume":"101","author":"Dunleavy","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.11.003_bib48","unstructured":"ECHELON-2: A Comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomas - Full Text View - ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01777152. Accessed August 5, 2016."},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2016.11.003_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/2.suppl_1.57","article-title":"PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)","volume":"2","author":"Philip","year":"1991","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.003_bib50","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1701596","article-title":"Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Fanin","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.hoc.2016.11.003_bib51","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bmt.1704392","article-title":"High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma","volume":"33","author":"Zamkoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib53","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.003_bib55","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib56","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2016.11.003_bib57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2016.11.003_bib58","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.hoc.2016.11.003_bib59","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/modpathol.2012.181","article-title":"Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls","volume":"26","author":"Jaffe","year":"2013","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib60","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-Cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.003_bib61","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"33","key":"10.1016\/j.hoc.2016.11.003_bib62","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib63","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2016.11.003_bib64","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.003_bib65","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer\/T Cell Lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"33","key":"10.1016\/j.hoc.2016.11.003_bib66","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.hoc.2016.11.003_bib67","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2016.11.003_bib68","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3109\/10428194.2010.487958","article-title":"Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer\/T cell lymphoma, nasal type","volume":"51","author":"Yokoyama","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.003_bib69","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.003_bib70","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer\/T-cell lymphoma, nasal type","volume":"52","author":"Ennishi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib71","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.003_bib72","unstructured":"Paper: comparison of autologous and allogeneic hematopoietic stem cell transplantation for extranodal NK\/T-Cell lymphoma, nasal type: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Available at: https:\/\/ash.confex.com\/ash\/2011\/webprogram\/Paper43317.html. Accessed July 14, 2016."},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib73","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/leu.2013.212","article-title":"Quantification of circulating Epstein-Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance","volume":"28","author":"Kwong","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.003_bib74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/aid.1993.9.381","article-title":"An HTLV-I vaccine: why, how, for whom?","volume":"9","author":"de Th\u00e9","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.hoc.2016.11.003_bib75","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological Aspects and World Distribution of HTLV-1 Infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.hoc.2016.11.003_bib76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.003_bib77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.hoc.2016.11.003_bib78","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib79","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A\u00a0new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"issue":"34","key":"10.1016\/j.hoc.2016.11.003_bib80","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib81","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.leukres.2006.10.012","article-title":"Multidrug resistance protein expression of adult T-cell leukemia\/lymphoma","volume":"31","author":"Yasunami","year":"2007","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.hoc.2016.11.003_bib82","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.V76.10.2065.2065","article-title":"Expression of P-glycoprotein in adult T-cell leukemia cells","volume":"76","author":"Kuwazuru","year":"1990","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.003_bib83","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.003_bib84","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.003_bib85","unstructured":"Paper: addition of anti-viral therapy to chemotherapy improves overall survival in acute and lymphomatous Adult T-Cell Leukaemia\/Lymphoma (ATLL). Available at: https:\/\/ash.confex.com\/ash\/2010\/webprogram\/Paper33893.html. Accessed July 25, 2016."},{"issue":"11","key":"10.1016\/j.hoc.2016.11.003_bib86","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","article-title":"Poor outcome of autologous stem cell transplantation for adult T\u00a0cell leukemia\/lymphoma: a case report and review of the literature","volume":"23","author":"Tsukasaki","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.003_bib88","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2016.11.003_bib89","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","article-title":"Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study","volume":"119","author":"Kanda","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.003_bib90","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.bbmt.2013.09.014","article-title":"Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T\u00a0cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study","volume":"19","author":"Ishida","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib91","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2015.265","article-title":"Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma","volume":"51","author":"Fuji","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2012-07-444372","article-title":"Treatment of relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience","volume":"121","author":"Itonaga","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2016.11.003_bib93","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.3390\/v7122960","article-title":"Recent advances in therapeutic approaches for adult T-cell Leukemia\/Lymphoma","volume":"7","author":"Kato","year":"2015","journal-title":"Viruses"},{"issue":"4 Suppl 1","key":"10.1016\/j.hoc.2016.11.003_bib94","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1053\/j.gastro.2005.02.027","article-title":"Association of celiac disease and intestinal lymphomas and other cancers","volume":"128","author":"Catassi","year":"2005","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.003_bib95","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.gcb.2010.09.008","article-title":"Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives","volume":"34","author":"Chandesris","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2016.11.003_bib97","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2011-10-385559","article-title":"How I treat enteropathy-associated T-cell lymphoma","volume":"119","author":"Di Sabatino","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.003_bib98","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0002-9440(10)65736-7","article-title":"Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology","volume":"153","author":"Chott","year":"1998","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib99","first-page":"1361","article-title":"Peripheral T-cell lymphomas of the intestine","volume":"141","author":"Chott","year":"1992","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.003_bib100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.dld.2012.12.001","article-title":"Enteropathy associated T\u00a0cell lymphoma in celiac disease: a large retrospective study","volume":"45","author":"Malamut","year":"2013","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000369542","article-title":"Enteropathy-associated T-cell lymphoma: improving treatment strategies","volume":"33","author":"Nijeboer","year":"2015","journal-title":"Dig Dis"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.003_bib102","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.2000.18.4.795","article-title":"Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center","volume":"18","author":"Gale","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib103","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.hoc.2016.11.003_bib104","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1200\/JCO.2003.06.026","article-title":"Intestinal non-Hodgkin\u2019s lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin\u2019s Lymphoma","volume":"21","author":"Daum","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004836-199509000-00012","article-title":"Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era","volume":"21","author":"Egan","year":"1995","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"18","key":"10.1016\/j.hoc.2016.11.003_bib106","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2016.11.003_bib107","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib108","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2016.11.003_bib109","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib110","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","article-title":"Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment","volume":"20","author":"Falchook","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib111","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","article-title":"Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience","volume":"13","author":"Voss","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.003_bib112","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2016.11.003_bib113","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood.V122.21.3032.3032","article-title":"Hepatosplenic T-Cell Lymphoma: clinicopathological features and treatment outcomes: report from the North American Peripheral T-Cell Lymphoma Consortium","volume":"122","author":"Shustov","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.11.003_bib114","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/cncr.20502","article-title":"Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature","volume":"101","author":"Go","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2016.11.003_bib116","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","article-title":"Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations","volume":"12","author":"Mehta","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.hoc.2016.11.003_bib117","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1200\/JCO.2012.41.5976","article-title":"Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma","volume":"30","author":"Bashey","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.003_bib118","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.12430","article-title":"Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC)","volume":"94","author":"Guillaume","year":"2015","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2016.11.003_bib119","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium","volume":"26","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2016.11.003_bib120","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.003_bib121","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-016-0271-4","article-title":"L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia","volume":"9","author":"Jung","year":"2016","journal-title":"J\u00a0Hematol Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881630171X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881630171X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:58Z","timestamp":1760184298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881630171X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S088985881630171X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T\/NK-cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}